HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via PHLDA1 Induction
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24076228 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Natasha S Clayton und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Wellcome Trust, Breast Cancer Now.
Abstract (Originalsprache)
The downregulation of Pleckstrin Homology-Like Domain family A member 1 (PHLDA1) expression mediates resistance to targeted therapies in receptor tyrosine kinase-driven cancers. The restoration and maintenance of PHLDA1 levels in cancer cells thus constitutes a potential strategy to circumvent resistance to inhibitors of receptor tyrosine kinases. Through a pharmacological approach, we identify the inhibition of MAPK signalling as a crucial step in PHLDA1 downregulation. Further ChIP-qPCR analysis revealed that MEK1/2 inhibition produces significant epigenetic changes at the PHLDA1 locus, specifically a decrease in the activatory marks H3Kme3 and H3K27ac. In line with this, we show that treatment with the clinically relevant class I histone deacetylase (HDAC) inhibitor 4SC-202 restores PHLDA1 expression in lapatinib-resistant human epidermal growth factor receptor-2 (HER2)+ breast cancer cells. Critically, we show that when given in combination, 4SC-202 and lapatinib exert synergistic effects on 2D cell proliferation and colony formation capacity. We therefore propose that co-treatment with 4SC-202 may prolong the clinical efficacy of lapatinib in HER2+ breast cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
ORCID-Profile: Pedro R Cutillas, Richard P Grose
Förderung
- Cancer Research UK
- Wellcome Trust
- Breast Cancer Now
- Barts Charity
Zitieren
APA
Clayton, N. S., Carter, E. P., Fearon, A. E., Heward, J. A., Rodríguez Fernández, L., Boughetane, L., Wilkes, E. H., Cutillas, P. R., & Grose, R. P. (2023). HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via PHLDA1 Induction. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076228
Vancouver
Clayton NS, Carter EP, Fearon AE, Heward JA, Rodríguez Fernández L, Boughetane L, et al. HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via PHLDA1 Induction. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076228
BibTeX
@article{Clayton2023,
author = {Clayton, Natasha S and Carter, Edward P and Fearon, Abbie E and Heward, James A and Rodríguez Fernández, Lucía and Boughetane, Lina and Wilkes, Edmund H and Cutillas, Pedro R and Grose, Richard P},
title = {HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via PHLDA1 Induction},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24076228}
}
EUVIMED